Leading law firm ROSEN alerts Biogen Inc. investors to the critical deadline for the BIIB securities class action lawsuit initiated by the firm.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Biogen Inc. (NASDAQ: BIIB) who purchased during the period from October 22, 2019, through November 6, 2020, inclusive (the “Class Period”), of the important deadline for lead plaintiff applications in this class action lawsuit. The lawsuit seeks to recover losses incurred by Biogen investors under the federal securities laws. The complaint alleges that defendants made false and/or misleading statements and/or failed to disclose throughout the Class Period that: (1) a larger dataset did not provide the necessary data regarding aducanumab’s efficacy; (2) the EMERGE study did not and could not provide the necessary data regarding aducanumab’s efficacy; (3) the PRIME study did not and could not provide the necessary data regarding aducanumab’s efficacy; (4) the data submitted by the Company to the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee did not support a finding of aducanumab’s efficacy; and (5) as a result, defendants’ statements regarding the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. The complaint further alleges that investors suffered losses when the truth entered the market. The law firm has already filed the class action lawsuit. If you wish to serve as lead plaintiff, you must apply to the Court no later than January 12, 2021. The lead plaintiff is the representative party who acts on behalf of other class members in directing the litigation.

Trusted top-tier investor counsel ROSEN encourages Discovery Inc. investors who sustained losses exceeding $100,000 to retain counsel before the critical March 8 deadline for the DISCA and DISCK securities class action lawsuit.

What does this mean: Individuals who purchased Discovery securities during the Class Period may be eligible to recover damages on a contingent fee basis, with no out-of-pocket fees or expenses. What to do next: To join the Discovery class action, please visit http://www.rosenlegal.com/cases-register-2239.html, call toll-free 866-767-3653, or email Phillip Kim, Esq. at pkim@rosenlegal.com or cases@rosenlegal.com for more information about the class action. The law firm has already filed the class action lawsuit. If you wish to serve as lead plaintiff, you must apply to the Court no later than March 8, 2022. The lead plaintiff is the representative party who acts on behalf of other class members in directing the litigation. Why choose ROSEN LAW: We encourage investors to select qualified attorneys with a proven track record of success in serving in leadership roles. Typically, law firms issuing such notices lack comparable experience, resources, or any rigorous peer recognition. Many such firms have never actually filed securities class actions. Numerous such firms do not litigate securities class actions at all but instead act merely as intermediaries—referring clients to, or partnering with, the firms that actually file and litigate the cases. Please choose your legal counsel wisely. Rosen Law Firm serves investors globally, focusing on securities class actions and shareholder derivative litigation. Rosen Law Firm initiated the largest securities class action ever filed against a Chinese company and successfully achieved a settlement. In 2017, Rosen Law Firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements it achieved. Since 2013, Rosen Law Firm has ranked among the top four firms annually on that list and has recovered hundreds of millions of dollars for investors. In 2019 alone, the firm recovered over $438 million for investors. In 2020, founding partner Laurence Rosen was named a "Titan of Plaintiffs’ Bar" by Law360.

SueWallSt Reminds Chemours Investors of Securities Class Action Deadline

Oct 22, 2026

SueWallSt.com notifies Chemours investors of a December 7, 2026 deadline for a class action lawsuit alleging misleading statements on Opteon refrigerant demand and 2026 financial guidance.

PR Newswire

2026-08-06

California AG Accuses DuPont of Shell Game to Dodge PFAS Cleanup

2026-09-05

Chemours, DuPont found liable for PFAS contamination in North Carolina properties; jury trial set for March

2026-09-23

Environmental groups allege Chemours hasn't met PFAS limits agreement

2026-10-11

The Chemours Company Sued for Securities Law Violations

2026-10-12

Faruqi & Faruqi Reminds Chemours Investors of Securities Class Action Deadline